Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  lapatinib ditosylate
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-1301, NCI-2013-01418, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
Temozolomide and Lapatinib Ditosylate in Treating Patients with Recurrent Low-Grade Ependymoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-N005, NCI-2012-02131, CERN 08-02, P152451, NCT00826241
Lapatinib Ditosylate and Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-437, NCI-2013-00670, NCT00881621
Lapatinib Ditosylate and Everolimus in Treating Patients with HER2 Positive Locally Advanced or Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2010-IIT-Novartis-RAD-001, NCI-2016-00027, HSC 12418, NCT01283789
Lapatinib Ditosylate, Temozolomide, and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LAP115352, NCI-2012-00779, 12-000493, NCT01591577
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery with or without Lapatinib Ditosylate in Treating Patients with Brain Metastasis from HER2-Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-1119, NCI-2012-01977, CDR0000735353, NCT01622868
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RF-3501, NCI-2014-01403, LAP116153, NCT01711658
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients with HER2-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1B-12-10, NCI-2013-01086, HS-13-00084, NCT01873833
Stereotactic Radiosurgery Followed by HER2 Directed Therapy in Treating Patients with HER2 Positive Breast Cancer with Newly Diagnosed Brain Metastasis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1345GCC, NCI-2015-02007, NCT01924351
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 117165, NCI-2016-00506, NCT02213042
Buparlisib or Alpelisib and Capecitabine, Trastuzumab, or Lapatinib Ditosylate in Treating Patients with Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1024, NCI-2013-00951, 11-0060, NCT01300962
Lapatinib Ditosylate and Bortezomib in Treating Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-533, NCI-2013-00659, NCT01497626
Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9354, NCI-2013-01748, 13-061, NCT01947023
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Status: Active
Phase: Phase I
Type: Treatment
Age: 1 to 21
Trial IDs: NMTRC012, NCI-2015-01822, NCT02559778
Intermittent High-Dose Lapatinib Ditosylate and Capecitabine in Treating Patients with HER2/Neu Positive Breast Cancer with Central Nervous System Metastases
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-278, NCI-2016-00341, NCT02650752
Trastuzumab, Pertuzumab, and Lapatinib Ditosylate in Measuring Kinome Response in Patients with HER2+ Breast Cancer Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: LCCC 1214, NCI-2014-01407, NCI-2014-00972, 13-1826, NCT01875666
Lapatinib Ditosylate before Surgery in Treating Patients with Recurrent High-Grade Glioma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ABTC-1302, NCI-2014-00634, NCT02101905
Veliparib and Lapatinib Ditosylate in Treating Patients with Triple Negative Metastatic Breast Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB1372, NCI-2015-00265, F131219003, NCI-2014-02253, NCT02158507
Start Over